Hot Features
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene the... uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 21.31 | 81.6162389889 | 26.11 | 48.73 | 25.97 | 994179 | 27.19300253 | CS |
| 4 | 22.43 | 89.7559023609 | 24.99 | 48.73 | 24 | 1330705 | 27.26926007 | CS |
| 12 | 31.8 | 203.585147247 | 15.62 | 48.73 | 13.21 | 1653871 | 22.63190013 | CS |
| 26 | 24.55 | 107.345867949 | 22.87 | 48.73 | 8.73 | 2550732 | 19.74842363 | CS |
| 52 | 32.41 | 215.922718188 | 15.01 | 71.5 | 8.73 | 2781613 | 28.91431847 | CS |
| 156 | 27.96 | 143.67934224 | 19.46 | 71.5 | 3.73 | 1920957 | 19.01581885 | CS |
| 260 | 13.3 | 38.98007034 | 34.12 | 71.5 | 3.73 | 1390237 | 19.59048572 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.